Roivant and Kinevant Sciences Complete Enrollment in Resolve-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis
Roivant和Kinevant Sciences完成了Resolve-Lung的入組,這是一項評估納米魯單抗治療慢性肺結節病的2期研究
Roivant and Kinevant Sciences Complete Enrollment in Resolve-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis
Roivant和Kinevant Sciences完成了Resolve-Lung的入組,這是一項評估納米魯單抗治療慢性肺結節病的2期研究
使用瀏覽器的分享功能,分享給你的好友吧